Maryland State Retirement & Pension System Has $2.16 Million Position in argenx SE (NASDAQ:ARGX)

Maryland State Retirement & Pension System raised its stake in shares of argenx SE (NASDAQ:ARGX) by 1.1% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 3,510 shares of the company’s stock after buying an additional 38 shares during the period. Maryland State Retirement & Pension System’s holdings in argenx were worth $2,159,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of the business. Whipplewood Advisors LLC bought a new position in argenx in the 4th quarter worth $37,000. Global Retirement Partners LLC boosted its position in shares of argenx by 369.2% during the 4th quarter. Global Retirement Partners LLC now owns 61 shares of the company’s stock valued at $38,000 after acquiring an additional 48 shares in the last quarter. Jones Financial Companies Lllp boosted its position in argenx by 1,016.7% in the fourth quarter. Jones Financial Companies Lllp now owns 67 shares of the company’s stock valued at $41,000 after buying an additional 61 shares in the last quarter. Farther Finance Advisors LLC boosted its position in argenx by 38.2% in the fourth quarter. Farther Finance Advisors LLC now owns 76 shares of the company’s stock valued at $47,000 after buying an additional 21 shares in the last quarter. Finally, Venturi Wealth Management LLC acquired a new position in argenx in the fourth quarter valued at about $66,000. Institutional investors own 60.32% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on ARGX shares. Robert W. Baird boosted their price target on shares of argenx from $650.00 to $680.00 and gave the company a “neutral” rating in a research report on Tuesday, March 4th. William Blair reissued an “outperform” rating on shares of argenx in a research note on Friday, February 28th. Piper Sandler boosted their price target on shares of argenx from $620.00 to $725.00 and gave the stock an “overweight” rating in a research note on Tuesday, January 7th. HC Wainwright upped their target price on shares of argenx from $717.00 to $720.00 and gave the company a “buy” rating in a research note on Friday, February 28th. Finally, Oppenheimer upped their price target on shares of argenx from $675.00 to $704.00 and gave the company an “outperform” rating in a report on Friday, February 28th. Three research analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $687.00.

argenx Stock Down 1.1 %

NASDAQ:ARGX opened at $613.04 on Friday. The stock has a market cap of $37.25 billion, a P/E ratio of -696.64 and a beta of 0.59. The firm’s fifty day simple moving average is $635.52 and its 200 day simple moving average is $598.47. argenx SE has a twelve month low of $352.77 and a twelve month high of $678.21.

argenx (NASDAQ:ARGX) last announced its earnings results on Thursday, February 27th. The company reported $1.58 EPS for the quarter, beating analysts’ consensus estimates of $0.98 by $0.60. The firm had revenue of $761.22 million for the quarter, compared to analysts’ expectations of $678.52 million. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. On average, analysts expect that argenx SE will post 3.13 EPS for the current fiscal year.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.